PC 01

Drug Profile

PC 01

Latest Information Update: 27 May 2002

Price : $50

At a glance

  • Originator Asahi Glass; Seikagaku Corporation
  • Developer Asahi Glass; Kaken Pharmaceutical; Meiji Seika Kaisha; Seikagaku Corporation
  • Class Oxidoreductases
  • Mechanism of Action Superoxide dismutase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Ulcerative colitis

Most Recent Events

  • 27 May 2002 Discontinued - Phase-II for Ulcerative colitis in Japan (unspecified route)
  • 27 May 2002 Discontinued - Phase-II for Amyotrophic lateral sclerosis in Japan (unspecified route)
  • 01 Mar 2001 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top